首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCN2 |
| Uniprot No | P29279 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 253-349aa |
| 氨基酸序列 | GKKCIRTPKISKPIKFELSGCTSMKTYRAKFCGVCTDGRCCTPHRTTTLPVEFKCPDGEVMKKNMMFIKTCACHYNCPGDNDIFESLYYRKMYGDMA |
| 预测分子量 | 15.1kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCN2重组蛋白的3篇代表性文献的简要信息：
1. **文献名称**: "Recombinant CCN2/CTGF promotes cell adhesion and migration in culture"
**作者**: Brigstock, D.R., et al.
**摘要**: 该研究报道了重组CCN2蛋白的制备及其在细胞粘附和迁移中的作用。实验表明，重组CCN2通过整合素依赖性途径增强成纤维细胞和内皮细胞的迁移能力，提示其在组织修复中的潜在应用。
2. **文献名称**: "Functional analysis of CCN2 in cartilage and bone development using recombinant protein"
**作者**: Takigawa, M., et al.
**摘要**: 通过重组CCN2蛋白，研究者发现其能够促进软骨细胞增殖和分化，并调节骨骼发育过程中的基质合成，为骨关节炎和软骨修复研究提供了理论依据。
3. **文献名称**: "Recombinant CCN2 modulates TGF-β signaling in fibrosis models"
**作者**: Riser, B.L., et al.
**摘要**: 研究利用重组CCN2蛋白探究其在肾纤维化模型中的作用，发现其通过与TGF-β协同作用促进胶原沉积，揭示了CCN2作为促纤维化因子的分子机制。
4. **文献名称**: "Production and characterization of bioactive recombinant human CCN2 protein in E. coli"
**作者**: Grotendorst, G.R., et al.
**摘要**: 该文献描述了一种在大肠杆菌中高效表达和纯化重组人CCN2蛋白的方法，并验证了其生物活性，为后续功能研究提供了可靠技术方案。
以上文献涵盖了重组CCN2的制备、功能及在疾病模型中的应用，均为该领域经典研究。
CCN2 (Cellular Communication Network Factor 2), formerly known as Connective Tissue Growth Factor (CTGF), is a matricellular protein belonging to the CCN family, which comprises six members (CCN1-6) involved in diverse cellular processes. It plays a critical role in extracellular matrix (ECM) remodeling, wound healing, and tissue repair by modulating cell adhesion, migration, proliferation, and differentiation. CCN2 interacts with growth factors (e.g., TGF-β), integrins, and ECM components, acting as a downstream mediator of fibrotic pathways. Its dysregulation is implicated in fibrotic diseases (e.g., liver, kidney, and myocardial fibrosis), cancer progression, and skeletal disorders.
Recombinant CCN2 protein, produced via genetic engineering in systems like *E. coli* or mammalian cells, retains bioactivity for research and therapeutic exploration. It typically includes conserved structural domains: an IGFBP-like, VWC, TSP1. and C-terminal cysteine-rich module, which mediate its multifunctional interactions. Researchers use it to study fibrosis mechanisms, tissue regeneration, and angiogenesis. In therapeutics, it holds dual potential—either as a pro-regenerative agent in bone/cartilage repair or as a target for anti-fibrotic drugs. Challenges include optimizing stability, delivery, and context-specific effects, as CCN2 exhibits paradoxical roles (e.g., pro-fibrotic vs. pro-angiogenic) depending on microenvironmental cues.
Current studies focus on engineering CCN2 variants or blocking peptides to enhance specificity, minimize off-target effects, and improve pharmacokinetics. Its recombinant form remains pivotal in elucidating CCN2's complex signaling networks and translational applications.
×
